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Abstract
Camptothecin (CPT; (S)-(+)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione) is a highly
cytotoxic natural alkaloid that has not yet found use as chemotherapeutic agent due to its poor water-solubility and chemical insta-
bility and, as a consequence, no effective administration means have been designed. In this work, camptothecin has been success-
fully loaded into iron oxide superparamagnetic nanoparticles with an average size of 14 nm. It was found that surface modification
of the nanoparticles by polyethylene glycol enables loading a large amount of camptothecin. While the unloaded nanoparticles do
not induce apoptosis in the H460 lung cancer cell line, the camptothecin-loaded nanoparticle formulations exhibit remarkable pro-
apoptotic activity. These results indicate that camptothecin retains its biological activity after loading onto the magnetic nanoparti-
cles. The proposed materials represent novel materials based on naturally occurring bioactive molecules loaded onto nanoparticles
to be used as chemotherapeutic formulations. The procedure seems apt to be extended to other active molecules extracted from
natural products. In addition, these materials offer the potential of being further implemented for combined imaging and therapeu-
tics, as magnetic nanoparticles are known to be multifunctional tools for biomedicine.
Introduction
Camptothecin (CPT) is a quinoline based alkaloid, which
exhibits a potent cytotoxic activity against a broad spectrum of
tumours [1-3]. While most antineoplastic agents inhibit cancer
cell proliferation by binding to DNA, CPT antitumor activity is
due to inhibition of the nuclear enzyme topoisomerase I [4,5].
In spite of its potential as chemotherapeutic agent, CPT suffers
from a reduced in vivo antitumor efficacy owing to its poor
water-solubility and chemical instability (Figure 1). CPT-
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Figure 2: Bright field (a) and dark field (b) transmission electron microscopy (TEM) images and diffraction pattern (c) of USM nanoparticles.
derivatives with improved solubility and stability have been
developed; nevertheless their overall therapeutic impact is
modest due to their lower activity when compared to CPT [6,7].
Figure 1: Molecular structure of (S)-(+)-camptothecin (1) and its inac-
tive form (2) through lactone ring hydrolysis at physiological pH.
An additional drawback related to the use of chemotherapeutic
drugs refers to their lack of selectivity and, consequently, to
their undesirable side effects. Due to the combined impact of
cancer together with adverse side effects of many conventional
chemotherapeutic agents, a significant effort is devoted to the
design of nanoparticle vectors for cancer therapy [8-10].
Concerning CPT, attempts to improve its solubility and stability
by means of nano-formulations cover a wide range of organic
nanomaterials [11-19]. Noticeably, a cyclodextrin-containing
polymer–CPT nano-formulation is currently undergoing phase
II clinical trials [20].
Superparamagnetic iron oxide nanoparticles (SPION) are partic-
ularly promising as delivery systems due to their low toxicity
and their ability to be used both in cancer diagnosis and therapy
[21-23]. SPION can be effectively used as contrast agents for
magnetic resonance imaging [24,25], as carriers for chemother-
apeutic drugs [26-28] and to destroy cancer cells by acting as
heat mediators in hyperthermia treatments [29-31]. Despite their
interest, few attempts to develop CPT-delivery systems based
on SPION have been reported [32-34], and none of them
examine their ability to adsorb CPT, nor takes advantage of the
desirable properties offered by polyethylene glycol (PEG) as
coating polymer in nano-formulations. PEG has been widely
used in the formulation of nanoparticles for biomedical applica-
tions, both because of its biocompatibility and its effectiveness
in camouflaging nanoparticles from opsonins [35]. Recently, it
has been described that PEG coating further reduces SPION
cytotoxicity [36]. Moreover, PEGylated CPT has demonstrated
its capability to lock the CPT E ring in its desired active lactone
configuration [37].
Herein, we report a simple method to synthesise PEG-coated
ultrasmall magnetite (USM) nanoparticles, and we examine the
ability of both, bare and PEGylated USM nanoparticles, to
conjugate CPT.
Findings
USM nanoparticles were synthesised through an iron co-precip-
itation method under alkaline conditions as described by Bee et
al. [38] with slight modifications [39] (for detailed descriptions
of the experimental procedures see Supporting Information
File 1). As shown in Figure 2a, the USM nanoparticles are
nearly spherical, with an average particle diameter of 14.0 nm
and a standard deviation of 2.0 nm, and monocrystalline
(Figure 2b). The electron diffraction pattern corresponds to the
spinel iron oxide nanocrystalline phase (Figure 2c).
Further insights into the crystalline structure were obtained
from X-ray diffraction (XRD) patterns. Figure 3 reports the
XRD pattern of our USM nanoparticles compared to a refer-
ence of a commercial magnetite standard. Although it is not
possible to unambiguously ascribe the obtained pattern for
USM nanoparticles to magnetite rather than to the isostructural
spinel ferric iron oxide (maghemite), the XRD sample of the
USM nanoparticles is consistent with the formation of
magnetite. The peak broadening of the XRD pattern of the
USM sample is in agreement with its nanocrystalline form. In
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Scheme 1: Carbodiimide-mediated covalent attachment of PEG to USM-Suc.
particular, the average size determined by line profile analysis is
11.0 ± 1.0 nm, in good agreement with the TEM data.
Figure 3: XRD spectrum of standard magnetite (a) and USM
nanoparticles (b).
The USM sample readily responds to an external magnet and
the main magnetic parameters, as derived by SQUID magne-
tometry characterisation, are summarised in Table 1. ZFC-FC
magnetisation curves indicate that the USM nanoparticles ex-
hibit a superparamagnetic behaviour and that most of the parti-
cles are blocked at room temperature, the blocking and
maximum temperatures being out of the investigated range. The
saturation magnetisation (Msat) as obtained from the hysteresis
curve collected at 5 K was measured to be around 72 emu·g−1
which is close to the value of bulk magnetite and maghemite
(ca. 90 and 80 emu·g−1, respectively). A decrease in saturation
magnetisation values is often observed in nanoparticles and
ascribed both to the effect of surface atoms and to a reduced
crystallinity compared to their bulk counterparts [40]. As shown
by the very low residual magnetisation value as compared to the
saturation magnetisation, the sample at 5 K is nearly saturated
at high fields and is mainly in the blocked state.
Table 1: Main magnetic parameters as derived for the USM sample by
SQUID magnetometry: Maximum and separation temperatures (Tmax
and Tsep) as obtained by ZFC-FC magnetization curves; coercive field
(Hc), saturation magnetization (Msat); residual magnetization (Mr) and
residual versus saturation magnetization values (Mr/Msat) as obtained
by the hysteresis curve collected at 5 K.
Tmax (K) Tsep (K) Hc (Oe) Mr
(emu/g)
Msat
(emu/g)
Mr/Msat
>325 >325 139.218 6.238 72.402 0.086
The obtained USM nanoparticles were PEGylated according to
the strategy depicted in Scheme 1. In a typical PEGylation
procedure the surface of USM nanoparticles was first coated
with succinic acid, in order to allow for the subsequent cova-
lent linkage of bis(3-aminopropyl)-terminated poly(ethylene
glycol) through carbodiimide chemistry.
It is known that the use of succinic acid as stabilizing agent
during the synthesis of magnetite nanoparticles decorates their
surface with acid molecules. Nevertheless, the amount of
succinic acid that has been attached to the surface is low, as can
be judged from the IR data available [41]. Given that the
amount of succinic linkers on the nanoparticle surface limits the
uptake of PEG, it is crucial to ensure higher amounts of
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carboxylic groups on the nanoparticle surface. In order to
increase the acid coating, we have investigated a different ap-
proach which relies on the direct incubation of previously
synthesized magnetite nanoparticles with the acid in aqueous
medium, instead of including it into the co-precipitation reac-
tion medium. By this approach we were able to obtain USM-
Suc nanoparticles whose surface is densely covered with
carboxylic acid.
Figure 4 shows the FTIR spectra of USM-Suc and succinic acid
in the most commonly used mode: transmittance. However, in
order to make a quantitative comparison between peak areas,
the corresponding absorbance spectra were used. The compari-
son between the areas of two peaks, one of succinic acid at
about 1467 cm−1, made up from a weaker contribution from
skeletal carbon in succinic acid (CH2 scissoring, 1419 cm−1)
and the symmetric stretching of the carboxylate group (around
1467 cm−1, total area = 11.2), and the other at 512 cm−1 that is
dependent on the amount of USM nanoparticles (δFe-O,
area = 6.6) yields an area ratio of 1.7. In comparison, the
skeletal carbon signal in [41] is virtually absent from the spec-
trum. According to our FTIR data we may reasonably assume
that the high succinic acid surface coating will translate into a
high coating of PEG in the subsequent functionalization step.
The FTIR spectrum, through the aforementioned symmetric
stretching of the carboxylate group plus the asymmetric
stretching at 1574 cm−1 supports that binding to the magnetic
core occurs through carboxylate groups, whereas free acid
groups are also detected in the spectrum (around 1700 cm−1)
that must be located on the outside of the particles, as illus-
trated in Scheme 1.
Figure 4: FTIR spectrum of USM-Suc nanoparticles (solid line) and
succinic acid (dotted line) as a reference. Highlighted signals are
discussed in the text.
In order to covalently attach the amino-terminated polymer
PEG onto the nanoparticle surface, a water soluble carbodi-
imide (N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride, EDC) was used that conjugates the primary
amine group of PEG with the free carboxylic end group of the
USM-Suc nanoparticles. EDC was used in tandem with
N-hydroxysuccinimide (NHS) to improve the water stability of
the carboxylic acid-activated intermediate, and excess PEG was
used for maximum coating of nanoparticles [42].
The comparison between the FTIR spectra of USM-Suc and
USM-PEG, Figure 4 and Figure 5 respectively, demonstrates
that the coupling reaction was successful. The characteristic
vibration of the succinic carboxylic acid group in USM-Suc
(C=O stretching mode at 1700 cm−1), disappears in USM-PEG
owing to its replacement by an amide bond (1638 cm−1). An
even clearer proof of the functionalization is the appearance of
intense characteristic bands of PEG at 2891 and 1103 cm−1,
corresponding to the ether C–H and C–O–C stretching modes,
respectively, and the band due to the remaining free primary
amine of PEG covalently bonded to the surface of USM (N–H
stretching) at 3419 cm−1.
Figure 5: FTIR spectrum of USM-PEG nanoparticles. Highlighted
signals are discussed in the text.
It is noteworthy that electrophoretic techniques have also been
developed in order to quantitatively determine the number of
PEG molecules in gold and quantum dot-PEG conjugates [43].
Loading of CPT on USM and USM-PEG nanoparticles was
performed by direct incubation of the drug in an aqueous solu-
tion of the nanoparticles to obtain the formulations USM[CPT]
and USM-PEG[CPT], respectively, and their maximum loading
capacity was calculated by Equation 1:
(1)
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Table 2: Maximum loading capacities of USM[CPT] and USM-PEG[CPT] nanoparticles calculated according to Equation 1 and compared to [33].
this work LC (%) reference [33] LC (%)
USM[CPT] 13.15 ± 0.05 CPT-loaded CS/Fe3O4 3.47 ± 0.09
USM-PEG[CPT] 26.11 ± 0.02 CPT-loaded OCMCS/Fe3O4 2.85 ± 0.05
CPT-loaded NSOCMCS/Fe3O4 3.01 ± 0.06
Figure 6: Infrared spectra of USM[CPT] (top, blue solid line), CPT (center, grey dotted line) and USM-PEG[CPT] (bottom, red solid line).
The loading capacity was obtained from UV assays according
to the details given in Supporting Information File 1, and the
results are summarized in Table 2. Both bare and PEGylated
nanoparticles were able to take up a substantial amount of CPT.
Although the loading capacity of USM bare nanoparticles was
not as high as the PEGylated ones, it is still higher than that
reported for other polymer-coated USM nanoparticles [33],
exceeding even the loading capacity of the prodrug Prothecan
(1.7% (w/w)) [44]. The extremely high loading capacity of
USM-PEG can be attributed to the amphiphilic nature of PEG
polymers. It is noteworthy that although PEG is commonly used
in block copolymers as hydrophilic moiety, it is soluble in both
water and organic solvents owing to the hydrophobic nature of
the ethylene groups. Although few examples are known in the
literature, PEG polymers have proven their ability to interact
with hydrophobic drugs [45].
The chemical integrity of CPT in USM[CPT] and USM-
PEG[CPT] was investigated by FTIR spectroscopy. As shown
in Figure 6 the characteristic peaks of CPT are clearly present in
both USM[CPT] and USM-PEG[CPT]. Although taken at a
lower resolution, probably due to the lower concentration of
CPT loaded in USM[CPT] when compared to USM-PEG[CPT],
the USM[CPT] formulation possesses also the characteristic
Beilstein J. Nanotechnol. 2014, 5, 1312–1319.
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Figure 7: A: Fluorescence microscopy images of H460 cell cultures: control (left); with bare USM (middle); with PEGylated USM (right). B: Fluores-
cence microscopy images of the H460 cell culture loaded with: CPT (left); USM[CPT] formulation (middle); USM-PEG[CPT] formulation (right) and
details of apoptotic nuclei (inserted). C: Percentage of apoptotic cell nuclei in H460 cell cultures: From left to right, control, with bare USM, with PEG-
ylated USM, with CPT, with USM[CPT], USM-PEG[CPT]. Stock dispersions of USM[CPT] and USM-PEG[CPT] were prepared in PBS (pH 7.5) with a
CPT concentration of 5 mM, and 1 µL of this dispersion was added to H460 cells previously cultured (confluent; 1mL final volume, 5 μM final CPT
concentration). Cells with nanoparticles and references were incubated at 37 °C for 48 h. More than 100 cells were examined for each experimental
condition. P < 0.05 significant differences with respect to control cells.
peaks of its CPT load. Differences in intensity and a shift are
expected and obtained between the characteristic bands of CPT
in USM[CPT] and USM-PEG[CPT], owing to the different
nature of the nanoparticle surface, which results in different
interactions with CPT. It is noteworthy that the characteristic
lactone band at 1750 cm−1 (C=O stretching vibration of lactone)
is retained in both USM[CPT] and USM-PEG[CPT] spectra,
indicating that the chemical integrity of CPT in nanoconjugates
is not affected during the formulation process.
As chemical integrity of CPT is related to its biological activity,
the formulations were tested in a biological setting for their effi-
ciency in inducing apoptosis. Apoptosis was assessed by the
occurrence of cells with nuclear condensation and fragmenta-
tion by Hoechst staining [46]. In order to compare the apoptotic
activity of USM[CPT] and USM-PEG[CPT] formulations,
stock solutions were prepared, and suitable amounts were taken
so that the provided final concentration of CPT was identical to
that used in the pure CPT control. According to our results,
neither USM nor USM-PEG nanoparticles induce apoptosis in
lung cancer cell line cultures H460, while USM[CPT] and
USM-PEG[CPT], as well as CPT itself, induced apoptosis
(Figure 7). The apoptotic levels obtained with both USM[CPT]
and USM-PEG[CPT] formulations are comparable to that
obtained with CPT. The slight activity decrease observed in
formulations when compared to CPT (about 10–15%) is prob-
ably due to the release profile of the drug from the formulations,
since an increase of the time during which the cell cultures are
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incubated with the formulations leads to an increased apoptosis
(data not shown).
In summary, two new CPT formulations based on iron oxide
superparamagnetic nanoparticles have been described and char-
acterized by FTIR. Both formulations retain the biological
activity of CPT and exhibit remarkable cytotoxic activity
towards H460 lung cancer cell line cultures. Remarkably, it was
found that iron oxide superparamagnetic nanoparticles synthe-
sized by co-precipitation method can be loaded with CPT. By
the proposed nanoparticle surface modification procedure with
PEG the amount of CPT that can be loaded was greatly
enhanced (in effect doubled) with respect to bare USM
nanoparticles. No significant difference in the cytotoxic activity
was observed among the CPT loaded on either the PEGylated or
bare USM magnetic nanoparticles. Nevertheless, a different in
vivo behaviour of PEGylated and non-PEGylated USM
nanoparticles cannot be ruled out, as longer circulation times
are expected for the PEGylated ones. Additionally, we envisage
that the developed USM-PEG may form targeted-delivery
systems by exploiting the free amine groups on their surface for
covalent attachment of targeting cargoes such as antibodies.
Supporting Information
Supporting Information File 1
General procedures.
[http://www.beilstein-journals.org/bjnano/content/
supplementary/2190-4286-5-144-S1.pdf]
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